• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Pfizer Inc.

    6/11/24 2:39:34 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PFE alert in real time by email
    11-K 1 pfizersavingsplan2023.htm 11-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549
    FORM 11-K
    FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS
    AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF
    THE SECURITIES EXCHANGE ACT OF 1934
     X ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES
    EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2023
    OR
    __ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    For the transition period from _______ to _______
    COMMISSION FILE NUMBER 1-3619
    A. Full title of the plan and the address of the plan, if different from that of the issuer named below:
    PFIZER SAVINGS PLAN
    B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:
    PFIZER INC.
    66 HUDSON BOULEVARD EAST
    NEW YORK, NEW YORK 10001-2192





    PFIZER SAVINGS PLAN

    Table of Contents

    Page
    Report of Independent Registered Public Accounting Firm
    1
    Financial Statements
    Statements of Net Assets Available for Plan Benefits as of December 31, 2023 and 2022
    3
    Statement of Changes in Net Assets Available for Plan Benefits for the year ended December 31, 2023
    4
    Notes to Financial Statements
    Beginning on page 5
    Supplemental Schedule*
    Schedule H, Line 4i - Schedule of Assets (Held at End of Year)
    Beginning on page 12
    Exhibit Index
    15
    Signature
    16
    *Note: Other schedules required by 29 CFR 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974, as amended, have been omitted because they are not applicable.




    Report of Independent Registered Public Accounting Firm


    To the Plan Participants and Savings Plan Committee
    Pfizer Savings Plan:

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for plan benefits of Pfizer Savings Plan (the Plan) as of December 31, 2023 and 2022, the related statement of changes in net assets available for plan benefits for the year ended December 31, 2023, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the net assets available for plan benefits of the Plan as of December 31, 2023 and 2022, and the changes in net assets available for plan benefits for the year ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Accompanying Supplemental Information

    The Schedule H, line 4i – Schedule of Assets (Held at End of Year) as of December 31, 2023 has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure
















    1


    under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ KPMG LLP

    We have not been able to determine the specific year that we or our predecessor firms began serving as the Plan’s auditor; however, we are aware that we or our predecessor firms have served as the Plan’s auditor since at least 1977.

    Memphis, Tennessee
    June 11, 2024
    2


    PFIZER SAVINGS PLAN
    STATEMENTS OF NET ASSETS AVAILABLE FOR PLAN BENEFITS

    As of December 31,
    (THOUSANDS OF DOLLARS)
    20232022
    Assets
    Investments, at fair value
    Pfizer Inc. common stock
    $1,189,164 $2,139,707 
    Common/collective trust funds
    13,926,536 12,323,972 
    Mutual funds
    845,657 1,036,146 
    Self-directed brokerage account
    360,452 280,342 
    Separate account
    1,387,679 — 
    Total investments, at fair value
    17,709,488 15,780,167 
    Investments, at contract value
    T. Rowe Price Stable Value Fund
    1,467,125 1,747,658 
    Total investments
    19,176,613 17,527,826 
    Receivables
    Company contributions
    375,389 332,462 
    Notes receivable from participants
    99,036 94,261 
    Securities sold
    490 4 
    Interest and other
    6,945 5,925 
    Total receivables
    481,861 432,652 
    Total assets
    19,658,473 17,960,478 
    Liabilities
    Payable for securities purchased
    3,308 3,225 
    Investment management fees payable
    2,387 1,002 
    Total liabilities
    5,695 4,228 
    Net assets available for plan benefits
    $19,652,778 $17,956,250 
    Amounts may not add due to rounding.
    See accompanying Notes to Financial Statements.
    3


    PFIZER SAVINGS PLAN
    STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR PLAN BENEFITS

    (THOUSANDS OF DOLLARS)
    Year Ended December 31, 2023
    Additions/(reductions) to net assets attributed to:
    Investment gain
    Net appreciation in investments
    $2,050,807 
    Pfizer Inc. common stock dividends
    68,322 
    Interest income
    73,467 
    Dividend income from other investments
    12,040 
    Total investment gain
    2,204,637 
    Interest income from notes receivable from participants
    5,392 
    Less: Investment management, redemption and loan fees
    (5,116)
    Net investment and interest gain
    2,204,913 
    Contributions
    Participant
    582,013 
    Company
    552,885 
    Rollovers into the Plan
    166,914 
    Total contributions
    1,301,812 
    Total additions
    3,506,725 
    Deductions from net assets attributed to:
    Benefits paid to participants
    1,852,186 
    Net increase
    1,654,539 
    Transfers into the Plan
    41,990 
    Net assets available for plan benefits
    Beginning of year
    17,956,250 
    End of year
    $19,652,778 
    Amounts may not add due to rounding.
    See accompanying Notes to Financial Statements.
    4


    PFIZER SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS

    1. Description of the Plan and Recent Transactions and Events

    The following description of the Pfizer Savings Plan (the Plan) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

    General

    The Plan is a defined contribution plan. Participation in the Plan is open to any employee of Pfizer Inc. (the Company or Plan Sponsor) or an affiliate which has, with the consent of the Plan Sponsor, adopted the Plan and who is included within a group or class designated by the Plan Sponsor as set forth in the Plan document. The Plan excludes any employees covered by another Company-sponsored defined contribution plan. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and the Internal Revenue Code of 1986, as amended (the Code).

    Recent Transactions and Events Impacting the Plan

    On November 17, 2021, the Company acquired Trillium Therapeutics Inc. (Trillium) and the Company adopted and assumed sponsorship of the Trillium Therapeutics USA, Inc. 401(k) Plan. On January 1, 2022, former Trillium employees who became employees of the Company, became eligible for participation in the Plan. All account balances totaling $0.4 million were transferred and merged into the Plan on July 12, 2022.

    On January 1, 2022, eligibility ceased for certain participants in the Plan as a result of the sale of Meridian Medical Technologies, Inc. (Meridian), a subsidiary of the Company, pursuant to the Stock Purchase Agreement by and among King Pharmaceuticals LLC, the Company, Meridian and MMT Acquisition Company, LLC dated November 1, 2021.

    On March 11, 2022, the Company acquired Arena Pharmaceuticals, Inc. (Arena) and adopted and assumed sponsorship of the ARENA Pharmaceuticals, Inc. 401(k) Plan. On August 1, 2022, former Arena employees who became employees of the Company, became eligible for participation in the Plan. All account balances totaling $63.9 million were transferred and merged into the Plan on November 1, 2022.

    On June 9, 2022, the Company acquired ReViral Ltd. (ReViral) and adopted and assumed sponsorship of the ReViral ADP TotalSource Retirement Savings Plan. On October 1, 2022, former ReViral employees who became employees of the Company, became eligible for participation in the Plan. All account balances totaling $0.1 million were transferred and merged into the Plan on April 25, 2023.

    On October 5, 2022, the Company acquired Global Blood Therapeutics, Inc. (GBT) and adopted and assumed sponsorship of the Global Blood Therapeutics Inc 401K Plan. On January 1, 2023, former GBT employees who became employees of the Company, became eligible for participation in the Plan. All account balances totaling $41.9 million were transferred and merged into the Plan on March 17, 2023.

    Plan Administration

    The Plan is administered by the Savings Plan Committee of the Company (the Plan Administrator), the named fiduciary of the Plan. The Plan Administrator monitors and reports on (i) the selection and termination of the trustee, custodian, investment managers and other service providers to the Plan and (ii) the investment activity and performance of the Plan, with the exclusion of the Company stock funds, which are monitored by State Street Global Advisors (SSGA), an independent fiduciary appointed by the Plan Administrator.

    Administrative Costs
    Plan participants pay quarterly fees from their account balances. These fees include general plan administrative fees and expenses, such as recordkeeping, trustee and independent fiduciary fees. The quarterly fee deductions take place on the first business day following the end of each quarter (and are deducted from any full account distribution occurring during a quarter). In addition, certain transaction fees such as check fees, loan fees and qualified domestic relations order fees are paid by Plan participants.

    5


    PFIZER SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    Contributions

    Participants may contribute up to 30% of their eligible compensation as before-tax, after-tax, Roth or a combination of these subject to annual IRS limits. For all participants, contributions of up to 3% of eligible compensation are matched 100% by the Company and the next 3% are matched 50% by the Company. Participant contributions in excess of 6% are not matched. Participants who have attained age 50 before the end of the Plan’s year are eligible to make catch-up contributions; however, these contributions are not matched.

    Company matching contributions are deposited into the Plan each quarter, rather than with each pay date. In addition, participants generally must be actively employed on the last business day of the quarter to receive the match; however, if the participant separates from the Company prior to the last business day of the quarter due to retirement (defined, as of January 1, 2022, as at least age 62 with at least 5 years of service, at least age 55 with at least 10 years of service or age 65), death or disability, such participant will receive the matching contribution. Starting in 2019, the Company began adding up to a total of five points to a participant’s age and/or service under certain U.S. separation programs to help those participants age 50 and older as of their termination date reach retirement milestones under certain benefits. One “point” equates to one year added to a participant’s age or service. If a participant exits the Company under one of the five point-eligible separation programs and, as of the termination date, is within five points of retirement treatment under the Plan, the participant will be deemed to have reached retirement eligibility without continued employment with the Company. These five points can be added to the participant’s age, service, or both (up to a total of five points), to help the participant reach retirement eligibility under the Plan. These five point enhancements under the programs continued through June 30, 2023. After that date, the Company’s separation programs no longer include the five point enhancements. In January 2023, the Company funded the fourth quarter 2022 Company matching contributions in the amount of approximately $34.9 million. In January 2024, the Company funded the fourth quarter 2023 Company matching contributions in the amount of approximately $39.6 million. These contributions are reported in the Company contributions receivable in the accompanying statements of net assets available for plan benefits.

    Under the Code, salary deferral contributions, total annual contributions and the amount of compensation that may be included for Plan purposes are subject to annual limitations. Any excess contributions are refunded to participants in the following year, as applicable.

    The Plan includes a Roth 401(k) in-plan conversion option, which allows participants to transfer after-tax dollars into the Roth account within the Plan and allows for tax-free earnings on those contributions. If subsequent distributions are considered “qualified Roth distributions” under the Code, such distributions are not subject to taxes.

    The Plan also includes a Retirement Savings Contribution (RSC), which is an additional annual Company-provided contribution based on age and years of service. With the exception of certain participants who are specifically excluded by the Plan terms, participants generally are eligible to receive the RSC. The RSC contributions are deposited into the Plan annually, following the close of the Plan year, usually in February. In general, participants must be actively employed on the last business day of the year to receive the RSC; however, if the participant separates from the Company prior to the last day of the year due to retirement (defined, as of January 1, 2022, as at least age 62 with at least 5 years of service, at least age 55 with at least 10 years of service or age 65), death or disability, such participant will receive the RSC. In February 2023, the Company funded the RSC for Plan year 2022 in the amount of approximately $297.6 million. In February 2024, the Company funded the RSC for Plan year 2023 in the amount of approximately $335.8 million. These contributions are reported in the Company contributions receivable in the accompanying statements of net assets available for plan benefits.

    Participant Accounts

    Each participant’s account is credited with the participant’s contributions, the Company’s contributions and an allocation of Plan earnings/(losses). Allocations are based on participants’ account balances, as defined in the Plan document.

    Vesting

    Participants are immediately 100% vested in their contributions and the Company matching contributions. However, for the RSC, participants are 100% vested after three years of credited service.






    6


    PFIZER SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    Forfeited Amounts

    Forfeited amounts of terminated participants are generally used to reduce future Company contributions. At December 31, 2023 and 2022, the market value of forfeitures available for use totaled approximately $1.4 million and $0.8 million, respectively. In 2023, Company contributions were reduced by approximately $5.4 million from forfeited amounts.

    Rollovers into the Plan

    Participants may elect to roll over one or more account balances from Company-sponsored or other qualified plans (including defined benefit plans) into the Plan.

    Investment Options

    Each participant in the Plan elects to have his or her contributions and Company contributions invested in any one or a combination of investment funds in the Plan, including a self-directed brokerage account. Transfers between funds must be made in whole percentages or dollar amounts. Based on the investment option, certain short-term redemption fees or restrictions may apply. Any contributions for which the participant does not provide investment direction are invested in the participant’s Qualified Default Investment Alternative (QDIA), which is the Vanguard Target Retirement Fund based on the participant’s year of birth.

    Eligibility

    Generally, all U.S.-based employees of the Company are eligible to enroll in the Plan on their date of hire, except for certain employees who (i) are covered by a collective bargaining agreement and have not negotiated to participate in the Plan, (ii) are employed by an employee group not designated for participation in the Plan, (iii) are covered by a collective bargaining agreement and have negotiated a different eligibility date or (iv) are otherwise eligible for another Company-sponsored savings plan.

    Newly eligible participants who do not affirmatively enroll in the Plan within 31 days of hire or transfer into eligible employment are automatically enrolled at a 6% before-tax contribution rate. Contributions are invested in the Plan’s QDIA fund based on the participant’s year of birth.

    Notes Receivable from Participants
    Participants may borrow from their account balances with the interest rate set at 1% above the prime rate. The minimum loan is $1,000 and the maximum loan is the lesser of (i) 50% of the vested account balance reduced by any current outstanding loan balance or (ii) $50,000, reduced by the current outstanding loan balance. Loans must be repaid within five years, unless the funds are used to purchase a primary residence. Primary residence loans must be repaid within 15 years. Loans transferred to the Plan due to the merger of legacy plans into the Plan maintain the terms of the original loan. Interest rates on outstanding loans ranged from 3.25% to 10.50% at December 31, 2023 and 2022.

    Interest paid by the participant is credited to the participant’s account. Interest income from notes receivable from participants is recorded by the trustee as earned in the investment funds in the same proportion as the original loan issuance. Repayments may not necessarily be made to the same fund from which the amounts were borrowed. Repayments are credited to the applicable funds based on the participant’s investment elections at the time of repayment.

    In the event of termination of employment, participants will have 90 days to repay the outstanding loan balance or set up recurring monthly payments before it is considered a distribution and subject to ordinary income tax in the year it is considered distributed. In addition, a 10% excise tax will generally apply if the participant is younger than age 59½ at the time the distribution occurs.

    Payment of Benefits

    Participants are entitled to receive distributions upon termination and may be able to take voluntary, in-service withdrawals, which include hardship withdrawals. Mandatory distributions are made in accordance with Plan provisions.


    7


    PFIZER SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS

    2. Summary of Significant Accounting Policies

    Basis of Accounting

    The financial statements of the Plan are prepared on the accrual basis of accounting.

    The statements of net assets available for plan benefits present the fair value of the Plan’s investments, except for the fully benefit-responsive investment contracts, which are reported at contract value (see Note 4). The statement of changes in net assets available for plan benefits is prepared on a contract value basis for the fully benefit-responsive investment contracts. All other assets are measured at fair value.

    Some amounts in the financial statements, notes to financial statements and supplemental schedule of the Plan may not add due to rounding.

    Use of Estimates

    The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires Plan management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

    Investment Valuation and Income Recognition

    Common stock and self-directed brokerage accounts are valued at the closing market price on the last business day of the year. Mutual funds are recorded at fair value based on the closing market prices obtained from national exchanges of the underlying investments of the respective fund as of the last business day of the year. Common/collective trust funds (CCTs) are stated at redemption value as determined by the trustees of such funds based upon the underlying securities stated at fair value on the last business day of the year. The Plan generally has the ability to redeem its investments at the net asset value (NAV) at the valuation date. There are no significant restrictions, redemption terms or holding periods that would limit the ability of the Plan or the participants to transact at the NAV. The Alliance Bernstein Large Cap Growth Equity Separate Account (Separate Account) primarily holds common stock and CCTs. The T. Rowe Price Stable Value Fund represents direct investments in Synthetic Investment Contracts (SICs) that are fully benefit-responsive and reported at contract value as contract value is the relevant measurement. See Note 4 for additional information.

    See Note 5 for additional information regarding the fair value of the Plan’s investments.

    Purchases and sales of securities are recorded on a trade-date basis. Dividend income is recorded on the ex-dividend date. Interest income is recorded as earned. The net appreciation/(depreciation) in the fair value of investments consists of the realized gains or losses on the sales of investments and the net unrealized appreciation/(depreciation) of investments.

    Notes Receivable from Participants

    Notes receivable from participants, which are subject to various interest rates, are recorded at amortized cost.

    Payment of Benefits

    Benefits are recorded when paid.
    3. Tax Status

    The Internal Revenue Service (IRS) has determined and informed the Plan Sponsor by letter dated April 18, 2018 that the Plan and related trust are designed in accordance with the applicable sections of the Code. The Plan has been amended since receiving the determination letter. However, the Company’s counsel believes the Plan is currently designed and being operated in compliance with the applicable requirements of the Code. Accordingly, no provision has been made for U.S. federal income taxes in the accompanying financial statements.

    U.S. GAAP requires Plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Company’s counsel has confirmed there are no uncertain positions taken that would require recognition of a liability (or
    8


    PFIZER SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. The Plan Administrator believes the Plan is generally no longer subject to income tax examinations for years prior to 2020.
    4. Investment Contracts

    Participants in the Plan have a stable value investment option that invests in the T. Rowe Price Stable Value Fund, which is composed of fully benefit-responsive SICs held directly. The contract value of the investment contracts represents contributions made under the contract and related earnings offset by participant withdrawals. There are no reserves against contract value for credit risk of the contract issuers or otherwise. The value of SICs held by the plan totaled approximately $1.5 billion and $1.7 billion as of December 31, 2023 and 2022, respectively.

    Investments underlying a synthetic structure are owned by a benefit plan or collective trust fund. SICs consist of a portfolio of underlying assets (which may include units of fixed income commingled or common trust funds) owned by a benefit plan or collective trust fund and a wrap contract issued by a financially responsible third party, typically an insurance company, bank or other financial services institution. The issuer of the wrap contract provides for unscheduled withdrawals from the contract at contract value, regardless of the value of the underlying assets, in order to fund routine permitted participant-initiated withdrawals from a stable value fund. SICs provide for a variable crediting rate, which typically resets at least quarterly, and the issuer of the wrap contract provides assurance that future adjustments to the crediting rate cannot result in a crediting rate less than zero.

    The crediting rate is based, in part, on the relationship between the contract value and the market value of the underlying assets, as well as previously realized gains and losses on underlying assets. The crediting rate will generally reflect, over time, movements in prevailing interest rates. However, at times the crediting rate may be more or less than prevailing rates or the actual income earned on the underlying assets. In most cases, realized and unrealized gains and losses on the underlying investments are not reflected immediately in the net assets of a stable value fund, but rather are amortized either over the time to maturity or the duration of the underlying investments, through adjustments to the future interest crediting rate.

    The existence of certain conditions can limit a benefit plan’s or collective trust fund’s ability to transact at contract value with the issuers of its investment contracts. Specifically, any event outside the normal operation of a benefit plan or collective trust which causes a withdrawal from an investment contract may result in a contract value adjustment with respect to such withdrawal. Examples of such events include, but are not limited to, partial or complete legal termination of the plan or collective trust fund, tax disqualification, certain plan or trust amendments if issuer consent is not obtained, improper communications to participants, group terminations, group layoffs, early retirement programs, mergers, sales, spin-offs and bankruptcy. The Plan Sponsor does not believe the occurrence of any such event is probable.

    In addition to the limitations noted above, issuers of investment contracts have certain rights to terminate a contract and settle at an amount that differs from contract value. For example, certain breaches by a benefit plan or the investment manager of their obligations, representations or warranties under the terms of an investment contract can result in its termination at market value, which may differ from contract value. Investment contracts may also provide for termination with no payment obligation from the issuer if the performance of the contract constitutes a prohibited transaction under ERISA or other applicable law. SICs may also provide issuers with the right to reduce contract value in the event an underlying security suffers a credit event or terminate the contract in the event certain investment guidelines are materially breached and not cured.
    5. Fair Value Measurements

    The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs to fair value measurements - Level 1 meaning the use of quoted prices for identical instruments in active markets; Level 2 meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and Level 3 meaning the use of unobservable inputs.

    See Note 2 for information regarding the methods used to determine the fair value of the Plan’s investments. These methods may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
    9


    PFIZER SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    The following tables set forth by level, within the fair value hierarchy, the Plan’s investments at fair value:
    Fair Value as of December 31, 2023
    (THOUSANDS OF DOLLARS)
    Level 1
    Level 2
    Total
    Pfizer Inc. common stock
    $1,189,164 $— $1,189,164 
    Common/collective trust funds
    — 13,926,536 13,926,536 
    Mutual funds
    845,657 — 845,657 
    Self-directed brokerage account
    360,452 — 360,452 
    Separate account:
    Common stock
    1,324,231 — 1,324,231 
    Common/collective trust funds
    — 63,448 63,448 
       Total
    $3,719,503 $13,989,984 $17,709,488 
    Fair Value as of December 31, 2022
    (THOUSANDS OF DOLLARS)
    Level 1
    Level 2
    Total
    Pfizer Inc. common stock
    $2,139,707 $— $2,139,707 
    Common/collective trust funds
    — 12,323,972 12,323,972 
    Mutual funds
    1,036,146 — 1,036,146 
    Self-directed brokerage account
    280,342 — 280,342 
       Total
    $3,456,195 $12,323,972 $15,780,167 
    Amounts may not add due to rounding.
    6. Related Party Transactions and Party-In-Interest Transactions

    Northern Trust, the trustee of the Plan, manages certain Plan investments and, therefore, is deemed a party-in-interest and a related party. Fidelity, the recordkeeper of the Plan, manages investments in its sponsored funds and, therefore, is deemed a party-in-interest and a related party. SSGA acts as an investment manager and independent fiduciary for the Plan Sponsor’s common stock and, therefore, is deemed a party-in-interest and a related party. The Plan also invests in shares of the Plan Sponsor; therefore, these transactions qualify as party-in-interest transactions.

    7. Plan Termination

    Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of termination of the Plan, each participant shall be entitled to the full value of his or her account balance as though he or she had retired as of the date of such termination. No part of the invested assets established pursuant to the Plan will at any time revert to the Company, except as otherwise permitted under ERISA.
    8. Risks and Uncertainties

    Investment securities, including Pfizer Inc. common stock, are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in their fair values will occur in the near term and that such changes could materially affect participants’ account balances and the amounts reported in the statements of net assets available for plan benefits.
    9. Subsequent Events

    On December 14, 2023, the Company acquired Seagen Inc. (Seagen) and adopted and assumed sponsorship of the Seagen Inc. 401(k) Plan. On January 1, 2024, former Seagen employees, who became employees of the Company, became eligible for participation in the Plan. All account balances totaling $564.9 million (including $2.4 million in loans) were transferred and merged into the Plan on February 27, 2024.

    The Plan Sponsor has evaluated subsequent events from the statement of net assets available for plan benefits date through June 11, 2024, the date at which the financial statements were issued, and no additional events were noted which warrant adjustments to, or disclosure in, the financial statements.

    10


    PFIZER SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    10. Reconciliation of Financial Statements to Form 5500

    Amounts allocated to withdrawing participants are recorded as benefits paid on Form 5500 for benefit claims processed and approved for payment prior to December 31st but not yet paid as of that date. Deemed distributions, representing withdrawing participants with outstanding loan balances for which no post-default payment activity has occurred, are not reported on Form 5500 in net assets available for plan benefits. Additionally, investments in the T. Rowe Price Stable Value Fund representing fully benefit-responsive investment contracts are reported on Form 5500 at fair value, whereas the net assets available for plan benefits in the financial statements report such investments at contract value.
    The following is a reconciliation of net assets available for plan benefits per the financial statements to the Form 5500:
    December 31,
    (THOUSANDS OF DOLLARS)
    20232022
    Net assets available for plan benefits per the financial statements$19,652,778 $17,956,250 
    Adjustment of T. Rowe Price Stable Value Fund from contract value to fair value(93,408)(128,216)
    Amounts allocated to withdrawing participants(6,959)(3,946)
    Deemed distributions(3,725)(3,441)
    Net assets available for plan benefits per Form 5500$19,548,686 $17,820,647 
    The following is a reconciliation of benefits paid, including rollovers, to participants per the financial statements to the Form 5500:
    (THOUSANDS OF DOLLARS)
    Year Ended December 31, 2023
    Benefits paid to participants, including rollovers, per the financial statements$1,852,186 
    Amounts allocated to withdrawing participants and deemed distributions at end of year
    10,684 
    Amounts allocated to withdrawing participants and deemed distributions at beginning of year
    (7,387)
    Benefits paid to participants, including rollovers, per Form 5500$1,855,483 
    The following is a reconciliation of net appreciation in investments per the financial statements to the Form 5500:
    (THOUSANDS OF DOLLARS)
    Year Ended December 31, 2023
    Net appreciation in investments per the financial statements
    $2,050,807 
    Adjustment of T. Rowe Price Stable Value Fund from contract value to fair value at end of year
    (93,408)
    Adjustment of T. Rowe Price Stable Value Fund from contract value to fair value at beginning of year
    128,216 
    Net appreciation in investments per Form 5500
    $2,085,615 
    11


    PFIZER SAVINGS PLAN
    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
    As of December 31, 2023
    (THOUSANDS OF DOLLARS)
    Identity of Issuer, Borrower, Lessor
     or Similar Party
    Description of InvestmentRate of InterestMaturity
    Date
    Cost****Current Value
    *Pfizer Inc. Common StockCommon stock$1,189,164 
    *NTGI Collective Government Short-Term
    Investment Fund
    Collective trust fund68,209 
    *
    Fidelity Large Cap Growth Fund
    Collective trust fund
    1,388,313 
    Boston Partners Large Cap Value FundCollective trust fund687,094 
    *SSGA S&P 500 Index FundCollective trust fund2,947,394 
    *SSGA International Equity Index FundCollective trust fund152,491 
    *
    SSGA Small-Mid Cap Equity Index Fund
    Collective trust fund
    1,043,659 
    Wellington International Equity Fund
    Collective trust fund
    356,716 
    Jennison Small-Mid Cap Equity Fund
    Collective trust fund
    257,259 
    Acadian International Equity Fund
    Collective trust fund
    356,970 
    *
    SSGA Bond Index Fund
    Collective trust fund
    24,152 
    Vanguard Target Retirement Income Trust Select
    Collective trust fund366,058 
    Vanguard Target Retirement 2020 Trust SelectCollective trust fund447,815 
    Vanguard Target Retirement 2025 Trust SelectCollective trust fund693,089 
    Vanguard Target Retirement 2030 Trust SelectCollective trust fund1,397,663 
    Vanguard Target Retirement 2035 Trust SelectCollective trust fund979,754 
    Vanguard Target Retirement 2040 Trust SelectCollective trust fund1,202,607 
    Vanguard Target Retirement 2045 Trust SelectCollective trust fund681,485 
    Vanguard Target Retirement 2050 Trust SelectCollective trust fund411,601 
    Vanguard Target Retirement 2055 Trust SelectCollective trust fund289,406 
    Vanguard Target Retirement 2060 Trust SelectCollective trust fund160,827 
    Vanguard Target Retirement 2065 Trust SelectCollective trust fund13,973 
    Total common/collective trust funds
    13,926,536 
    T. Rowe Price Small Cap Stock FundMutual fund257,259 
    Diversified Bond Fund – CoreMutual fund529,558 
    Diversified Bond Fund – High YieldMutual fund14,710 
    Diversified Bond Fund - Emerging MarketsMutual fund29,420 
    Diversified Bond Fund - Opportunities Income
    Mutual fund
    14,710 
    Total mutual funds845,657 
    Self-Directed Brokerage AccountSelf-directed brokerage account360,452 

    12


    PFIZER SAVINGS PLAN
    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
    As of December 31, 2023
    (THOUSANDS OF DOLLARS)
    (continued)
    Identity of Issuer, Borrower, Lessor
     or Similar Party
    Description of InvestmentRate of InterestMaturity
    Date
    Cost****Current Value
    Separate Account –
    Genmab Common Stock
    Common stock
    8,255 
    Ferrari Common Stock
    Common stock
    9,562 
    ADR ASML Holding Common Stock
    Common stock
    9,306 
    Adobe Inc. Common Stock
    Common stock
    24,172 
    Align Technology Inc. Common Stock
    Common stock
    5,892 
    Alphabet Inc. Common Stock
    Common stock
    68,627 
    Amazon Inc. Common Stock
    Common stock
    70,958 
    Ametek Inc. Common Stock
    Common stock
    8,467 
    Amphenol Corp. Common Stock
    Common stock
    5,738 
    Arista Networks Inc. Common Stock
    Common stock
    30,487 
    Autodesk Inc. Common Stock
    Common stock
    5,345 
    Broadcom Inc. Common Stock
    Common stock
    11,112 
    Cadence Design Sys Inc. Common Stock
    Common stock
    10,672 
    Chipotle Mexican Grill Inc. Common Stock
    Common stock
    18,568 
    Cognex Corp. Common Stock
    Common stock
    2,201 
    Copart Inc. Common Stock
    Common stock
    30,771 
    Costco Wholesale Corp. Common Stock
    Common stock
    41,655 
    Crowdstrike Holdings Inc. Common Stock
    Common stock
    11,903 
    Edwards Lifesciences Corp. Common Stock
    Common stock
    20,881 
    Eli Lilly & Co. Common Stock
    Common stock
    33,428 
    Entegris Inc. Common Stock
    Common stock
    5,784 
    Fortinet Inc. Common Stock
    Common stock
    26,763 
    Home Depot Inc. Common Stock
    Common stock
    18,813 
    Idexx Labs Inc. Common Stock
    Common stock
    26,557 
    Intuitive Surgical Inc. Common Stock
    Common stock
    39,523 
    Lululemon Athletica Inc. Common Stock
    Common stock
    26,005 
    Manhattan Associates Inc. Common Stock
    Common stock
    9,016 
    Meta Platforms Inc. Common Stock
    Common stock
    21,730 
    Mettler-Toledo International Inc. Common
       Stock
    Common stock
    7,919 
    Microsoft Corp. Common Stock
    Common stock
    134,024 
    Monster Beverage Corp. Common Stock
    Common stock
    45,626 
    Motorola Solutions Inc. Common Stock
    Common stock
    16,465 
    MSCI Inc. Common Stock
    Common stock
    12,272 
    Netflix Inc. Common Stock
    Common stock
    25,860 
    Nike Inc. Common Stock
    Common stock
    17,766 
    Nvidia Corp. Common Stock
    Common stock
    67,563 
    Otis Worldwide Corp. Common Stock
    Common stock
    17,210 
    Paycom Software Inc. Common Stock
    Common stock
    10,564 
    Qualcomm Inc. Common Stock
    Common stock
    30,791 
    Roper Technologies Inc. Common Stock
    Common stock
    25,561 
    Servicenow Inc. Common Stock
    Common stock
    11,878 
    Sherwin-Williams Co. Common Stock
    Common stock
    19,329 
    Synopsys Inc. Common Stock
    Common stock
    10,046 
    Tractor Supply Co. Common Stock
    Common stock
    8,021 
    Trex Co Inc. Common Stock
    Common stock
    6,961 
    Tyler Technologies Inc. Common Stock
    Common stock
    5,127 
    Unitedhealth Group Inc. Common Stock
    Common stock
    72,940 
    13


    PFIZER SAVINGS PLAN
    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
    As of December 31, 2023
    (THOUSANDS OF DOLLARS)
    (continued)
    Identity of Issuer, Borrower, Lessor, or Similar PartyDescription of InvestmentRate of InterestMaturity DateCost****Current Value
    Veeva Sys Inc. Common Stock
    Common stock
    21,751 
    Verisk Analytics Inc. Common Stock
    Common stock
    13,264 
    Vertex Pharmaceuticals Inc. Common Stock
    Common stock
    40,142 
    Visa Inc. Common Stock
    Common stock
    62,540 
    Waters Corp. Common Stock
    Common stock
    8,103 
    Zoetis Inc. Common Stock
    Common stock
    30,318 
    Total common stock
    1,324,231 
    *
    NTGI Collective Government Short-Term
       Investment Fund
    Collective trust fund
    63,448 
    Total separate account
    1,387,679 
    T. Rowe Price Stable Value Fund –
    ***American General Life Insurance Company Contract #GA-IM-266-1658155Synthetic investment contract2.92 %**129,950 
    ***
    JPMorgan Securities, LLC
    Contract #ATRPPFIZER 01
    Synthetic investment contract2.54 %**129,016 
    ***
    New York Life Insurance Company
    GIC Contract #GA-29302
    Synthetic investment contract2.70 %**146,257 
    ***
    The Prudential Insurance Company of
    America Contract #GA-63191
    Synthetic investment contract2.66 %**174,048 
    ***
    Royal Bank of Canada Contract
    #TRPPFIZER01
    Synthetic investment contract2.78 %**114,573 
    ***
    State Street Bank and Trust Company
    Contract #96028
    Synthetic investment contract2.47 %**202,701 
    ***
    Massachusetts Mutual Life Insurance
    Company Contract #30011
    Synthetic investment contract2.41 %**149,649 
    ***
    Metropolitan Life Insurance Company
    Contract #38127
    Synthetic investment contract2.86 %**186,324 
    ***Pacific Life Insurance Company Contract #G-27852.01.001Synthetic investment contract2.63 %**115,942 
    *** Lincoln National Life Insurance Company Contract # BVW0108T Synthetic investment contract2.70 %**118,664 
    Total T. Rowe Price Stable Value Fund
    1,467,125 
       Total investments
    19,176,613 
    *Notes receivable from participantsInterest Rates: 3.25% - 10.50%99,036 
    Maturity Dates: 2024 - 2038
    Total$19,275,649 
    *
    Party-in-interest as defined by ERISA
    **Open-ended maturity
    ***Current value represents contract value
    ****Cost information omitted as all investments are fully participant-directed. This information is not required by ERISA or the Department of Labor to be reported for participant-directed investments.
    Amounts may not add due to rounding.
    See accompanying Report of Independent Registered Public Accounting Firm.
    14


    Exhibit Index
    Exhibit 23.1
    -
    Consent of Independent Registered Public Accounting Firm

    15


    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the members of the Savings Plan Committee have duly caused this annual report to be signed on its behalf by the undersigned thereunto duly authorized.
    PFIZER SAVINGS PLAN
    By: /s/ Colum Lane
    Colum Lane
    Member, Savings Plan Committee
    Date: June 11, 2024
    16
    Get the next $PFE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PFE

    DatePrice TargetRatingAnalyst
    1/7/2026$25.00Neutral
    UBS
    12/2/2025$26.00Neutral
    Citigroup
    11/13/2025$30.00Sector Outperform
    Scotiabank
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    12/10/2024$29.00Neutral
    BofA Securities
    11/15/2024$25.00Underperform
    Wolfe Research
    10/25/2024$30.00Neutral
    Citigroup
    10/17/2024$32.00Mkt Perform
    Bernstein
    More analyst ratings

    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, R&D Boshoff Christoffel covered exercise/tax liability with 12,887 shares, decreasing direct ownership by 8% to 155,645 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/2/26 5:55:49 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    1/16/26 2:32:11 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Buckley Mortimer J

    4 - PFIZER INC (0000078003) (Issuer)

    1/5/26 4:59:41 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

    Submission is to expand HYMPAVZI indication to the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) without inhibitors If approved, HYMPAVZI would become the first non-factor prophylactic treatment available for children aged 6 to 11 years with hemophilia B Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patient

    2/6/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

    Program offers significant savings on over 30 brands spanning women's health, migraine, arthritis, rare disease and more Affirms Pfizer's commitment to reduce drug costs for millions of Americans through historic agreement with Trump administration Pfizer Inc. (NYSE:PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer's broader landmark Most Favored Nation (MFN) agreement with the U.S. government enabling patients to pay lower prices for

    2/5/26 7:09:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

    Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc

    2/3/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    12/19/23 9:31:01 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Pfizer with a new price target

    UBS resumed coverage of Pfizer with a rating of Neutral and set a new price target of $25.00

    1/7/26 9:13:33 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup resumed coverage on Pfizer with a new price target

    Citigroup resumed coverage of Pfizer with a rating of Neutral and set a new price target of $26.00

    12/2/25 8:29:06 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Pfizer with a new price target

    Scotiabank initiated coverage of Pfizer with a rating of Sector Outperform and set a new price target of $30.00

    11/13/25 9:16:05 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    SEC Filings

    View All

    Pfizer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PFIZER INC (0000078003) (Filer)

    2/3/26 7:01:37 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PFIZER INC (0000078003) (Filer)

    12/16/25 7:01:53 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Pfizer Inc.

    8-K - PFIZER INC (0000078003) (Filer)

    11/21/25 4:16:49 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dexcom Appoints Jon Coleman as Chief Commercial Officer

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

    3/25/25 4:05:00 PM ET
    $DXCM
    $MASI
    $PFE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    $PFE
    Financials

    Live finance-specific insights

    View All

    Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

    Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc

    2/3/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. Abou

    1/5/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen

    12/18/25 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pfizer Inc. (Amendment)

    SC 13G/A - PFIZER INC (0000078003) (Subject)

    2/9/23 11:30:22 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Pfizer Inc.

    SC 13D - PFIZER INC (0000078003) (Filed by)

    7/27/22 4:42:06 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pfizer Inc. (Amendment)

    SC 13G/A - PFIZER INC (0000078003) (Subject)

    2/10/22 8:32:46 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care